How to Cope With Pituitary Tumor Anxiety and Stigma?
At a Glance
A prolactinoma is usually a noncancerous pituitary tumor treated first with oral medicines, not chemotherapy. Anxiety, stigma, and scan-related stress are real; clear information, support, therapy, and a plan for warning symptoms can make coping easier.
In this answer
4 sections
Hearing that you have a “pituitary tumor” is often terrifying. It is completely understandable for your mind to immediately jump to worst-case scenarios like brain cancer or intensive chemotherapy. However, if your doctor has confirmed that your tumor is a prolactinoma (a pituitary tumor that secretes the hormone prolactin), the reality is very different. You can cope with this diagnosis by understanding three stabilizing medical facts: these growths are overwhelmingly benign (not cancer), they sit in a bony pocket beneath the brain rather than inside your brain tissue, and they are typically treated with oral medications rather than surgery or chemotherapy.
Decoding the Word “Tumor”: Three Stabilizing Facts
When doctors use the word “tumor,” they simply mean an abnormal growth of cells. To ease the panic that often comes with this word, keep these facts in mind:
- Nearly all prolactinomas are benign: A benign tumor is a non-cancerous growth that does not spread to other parts of the body like cancer does [1] [2]. While “benign” does not mean harmless—the tumor still requires medical care because of its size and hormone production—true pituitary carcinomas (cancers of the pituitary gland) are exceptionally rare, making up less than 0.2% of all pituitary tumors [3] [4].
- It is not inside your brain tissue: A prolactinoma arises in the pituitary gland (a pea-sized organ that produces hormones), which sits at the base of the skull in a protective bony pocket [5]. While a large tumor can press on nearby structures like the optic nerves, it is not an infiltrating brain tumor growing inside the brain tissue itself [6].
- Medication is usually the first step: Unlike most tumors, prolactinomas are highly responsive to dopamine agonists (oral medications, such as cabergoline or bromocriptine, that mimic the brain chemical dopamine to lower prolactin production) [7]. At a population level, these medications normalize prolactin and shrink the tumor in the majority of patients [8]. If the medication is ineffective, causes severe side effects, or if your vision is threatened, surgery may be recommended [7] [9]. Chemotherapy is almost never used unless dealing with exceptionally rare, aggressive cases [7] [10].
The Emotional Toll is Real
The stigma of a “brain tumor” diagnosis can make you feel isolated, but the anxiety, depression, and fatigue you are experiencing are very common among patients with hyperprolactinemia [11] [12].
These emotional burdens can have many causes, including the stress of the diagnosis itself, the effects of the hormonal imbalance on your body, or changes in other pituitary hormones [11] [12]. A prolactinoma can decrease your overall quality of life, particularly in mental and psychosocial areas [13].
While many patients see improvements in their mood and energy as treatment begins to shrink the tumor and lower prolactin levels, recovery varies from person to person [13]. If your anxiety or depression persists, it is important to seek separate psychological support.
A note on medication: Dopamine agonists can sometimes cause side effects. While nausea, dizziness, and headaches are most common, they can rarely cause changes in mood or impulse control (such as new compulsive gambling, spending, binge eating, or sexual behavior) [14] [11]. If you notice these changes, do not stop taking the medication on your own, but contact your prescriber promptly [14].
Managing Stigma and “Scanxiety”
The word “tumor” carries a heavy stigma. When talking to family, friends, or employers who might overreact, it can help to use a prepared script, such as: “I have a non-cancerous, hormone-producing pituitary tumor that is commonly treated with medication.”
Monitoring a prolactinoma requires individualized MRI scans, which can trigger intense anxiety leading up to the appointment and while waiting for results—a phenomenon commonly called scanxiety [15]. Here are practical ways to manage it:
- Clarify the timeline: Anxiety thrives in uncertainty. Ask your care team exactly when and how you will receive your MRI results [15] [16].
- Prepare for the scan: If you experience claustrophobia, ask your doctor in advance about accommodations, bringing a support person, or whether medication for severe scan anxiety is an option.
- Use structured coping techniques: Evidence shows that structured psychological approaches like cognitive-behavioral therapy (CBT) and mindfulness-based interventions can significantly reduce medical anxiety and fear [17] [18]. A therapist familiar with chronic illness can help you process the stigma of the word “tumor” and give you tools to calm your nervous system [17].
When to Seek Urgent Care
While prolactinomas grow slowly, a large tumor can press on nearby structures or rarely experience sudden complications [6] [9]. Seek urgent medical attention or go to an emergency room if you experience:
- A sudden, severe headache
- New or worsening vision loss (especially in your peripheral vision) or double vision
- Severe vomiting, sudden confusion, or extreme weakness
These symptoms require prompt medical evaluation, which is a separate step from managing routine anticipatory anxiety.
Common questions in this guide
Is a prolactinoma the same as brain cancer?
How is a prolactinoma usually treated?
How can I manage anxiety and stigma after a pituitary tumor diagnosis?
Can a prolactinoma or its medicine affect my mood?
When should I seek urgent care for a prolactinoma?
Related questions
Show more
Get notified when new evidence is published on acquired hyperprolactinemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Aggressive and Malignant Prolactinomas.
Olarescu NC, Perez-Rivas LG, Gatto F, et al.
Neuroendocrinology 2019; (109(1)):57-69 doi:10.1159/000497205.
PMID: 30677777 - 2
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
Ho KKY, Kaiser UB, Chanson P, et al.
Nature reviews. Endocrinology 2023; (19(11)):671-678 doi:10.1038/s41574-023-00883-8.
PMID: 37592077 - 3
The epidemiology of aggressive pituitary tumors (and its challenges).
Dekkers OM, Karavitaki N, Pereira AM
Reviews in endocrine & metabolic disorders 2020; (21(2)):209-212 doi:10.1007/s11154-020-09556-7.
PMID: 32361816 - 4
Prolactin Secreting Pituitary Carcinoma and the Role of Peptide Receptor Radionuclide Therapy: A Brief Report.
Agarwal N, Verma SK, Gopinathan VR, et al.
Neurology India 2024; (72(4)):871-876 doi:10.4103/neurol-india.Neurol-India-D-24-00529.
PMID: 39216050 - 5
Current approach to treatments for prolactinomas.
Tirosh A, Shimon I
Minerva endocrinologica 2016; (41(3)):316-23.
PMID: 26399371 - 6
GIANT PROLACTINOMA. A CASE REPORT.
Šulavíková Z, Krásnik V
Ceska a slovenska oftalmologie : casopis Ceske oftalmologicke spolecnosti a Slovenske oftalmologicke spolecnosti 2023; (79(3)):143-148 doi:10.31348/2023/20.
PMID: 37344216 - 7
Treatment of Prolactinoma.
Inder WJ, Jang C
Medicina (Kaunas, Lithuania) 2022; (58(8)) doi:10.3390/medicina58081095.
PMID: 36013562 - 8
Prolactin-secreting adenomas: pathogenesis, diagnosis, and management.
Fleseriu M, Varlamov EV, Akirov A, et al.
The lancet. Diabetes & endocrinology 2025; (13(10)):874-890 doi:10.1016/S2213-8587(25)00227-X.
PMID: 40876473 - 9
Update on prolactinomas. Part 1: Clinical manifestations and diagnostic challenges.
Wong A, Eloy JA, Couldwell WT, Liu JK
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2015; (22(10)):1562-7.
PMID: 26256063 - 10
Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology 2019; (109(1)):42-50 doi:10.1159/000495775.
PMID: 30481756 - 11
Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas.
Ioachimescu AG, Fleseriu M, Hoffman AR, et al.
European journal of endocrinology 2019; (180(1)):31-40.
PMID: 30400048 - 12
Reduced Health Related Quality of Life, Increased Fatigue, and Daytime Sleepiness in Women with Hyperprolactinemia.
Ernersson Å, Bachrack-Lindström M, Landberg E, et al.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 2023; (55(4)):266-272 doi:10.1055/a-2042-0712.
PMID: 36822222 - 13
Quality of life in Prolactinoma: A systematic review.
Castle-Kirszbaum M, Biermasz N, Kam J, Goldschlager T
Pituitary 2024; (27(3)):239-247 doi:10.1007/s11102-024-01392-1.
PMID: 38656635 - 14
Prevalence and risk factors of dopamine agonists induced impulse control disorders in patients with prolactinoma.
Zhang S, Wang C, Wang D
International journal of psychiatry in medicine 2026; (61(3)):294-311 doi:10.1177/00912174251392426.
PMID: 41165051 - 15
Scan-Associated Distress in People Affected by Cancer: A Qualitative Systematic Review.
Hussain M, Chau S, Turner M, Paterson C
Seminars in oncology nursing 2023; (39(5)):151502 doi:10.1016/j.soncn.2023.151502.
PMID: 37735038 - 16
Systematic review of interventions by non-mental health specialists for managing fear of cancer recurrence in adult cancer survivors.
Liu JJ, Butow P, Beith J
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2019; (27(11)):4055-4067 doi:10.1007/s00520-019-04979-8.
PMID: 31286237 - 17
Effectiveness Comparisons of Various Psychological Therapies for Fear of Cancer Recurrence in Cancer Patients: A Systematic Review and Network Meta-Analysis.
Wang T, Chen L, Tang C, et al.
Psycho-oncology 2026; (35(6)):e70509 doi:10.1002/pon.70509.
PMID: 42216873 - 18
Intervention and mediation effects of target processes in a randomized controlled trial of Acceptance and Commitment Therapy for anxious cancer survivors in community oncology clinics.
Fishbein JN, Judd CM, Genung S, et al.
Behaviour research and therapy 2022; (153()):104103 doi:10.1016/j.brat.2022.104103.
PMID: 35504144
This page is for informational purposes only and does not constitute medical advice. It cannot replace individualized guidance from your healthcare professional about prolactinoma treatment, mental health symptoms, medication side effects, or urgent warning signs.